ジャパンタイムズ18h
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
Prediction: this FTSE 250 trust will beat Rolls-Royce shares over the next 5 years
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...
Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year
Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a mixed bag. But headwinds, like tariffs and drug pricing, are clearly blowing ...
Daily23h
USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma
Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...